- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06161883
Effect of Tomato Soffritto Intake on Biomarkers of Cardiovascular Disease in an Overweight and Obesity (FRITOCARD)
Effect of the Intake of a Tomato Sofrito Preparation on Biomarkers of Cardiovascular Disease in an Overweight and/or Obese Population
Study Overview
Detailed Description
Sample size (N= 40) was calculated according results of previous studies on pigs (http://dx.doi.org/10.1016/j.trsl.2014.11.004). The study refers to healthy adult men (n=27) and women (n=13) with ages ranging from 25 to 60 years, non-smokers and with overweight (BMI: 25.0-29.9 kg/m2) or obesity class 1 (BMI: 30-34.9 kg/m2).
This study received approval from the Human Ethical Review Committee of Hospital Santa Creu I Sant Pau (Barcelona), with the reference number 12/181 and the date of approval being January 11, 2013. To confirm health status, all subjects underwent a complete physical examination conducted by the study physician.
The study lasted 16 weeks that were structured in:
- 2 weeks of run-in.
- 6 weeks of intervention period. During the intervention period, volunteers were administered with soffritto (100 g/day) or a control group (without soffritto).
- 2 weeks of wash-out.
- 6 weeks of intervention period. During the intervention period, volunteers exchanged their interventions
The volunteers visited the center at days 0, 14, 56, 70 and at the end of the intervention period (day 112).
Dietary habits were collected. Compliance was monitored by weekly telephone contact with participants and interviewing them at the end of each intervention period. Blood samples were collected early at the morning after twelve-hour fasting at baseline and at the end of each intervention phase. Blood samples were used for determining all variables of the study. Stool samples were obtained at baseline and after 42 days intervention for the study of platelet aggregation, lipid profile, biochemical measurements, vascular endothelial function and hemogram profile.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Barcelona, Spain, 08025
- Institut Recerca-Hospital Santa Creu I Sant Pau
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Men and Women 25-60 years of age
- BMI: >28 Kg/m2
Exclusion Criteria:
- Ischemic heart disease (and/or previous angina or AMI)
- Less than 25 years old and more than 60 years old
- Current/previous history of arrhythmia
- Cardiovascular co-morbidity (previous cardiovascular accidents and/or peripheral vascular disease)
- On current treatment with vasoactive drugs, fibrates or statins (see exception)
- Alcohol consumption of more than 60 gr/day
- Renal insufficiency (creatinine > 2 mg/dl)
- Presence of neoplasia
- Presence of systemic disease
- Psychiatric disease in treatment with psychotropic drugs
- Secondary dyslipidemia (nephrotic syndrome, hypothyroidism, others...)
- Being in a weight loss phase or expressing a desire for weight loss during the 3 months of the study duration.
- Having taken aspirin in the 10-day period prior to blood sampling.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Soffritto group
After a two-week run-in phase, participants (N=20) were randomly assigned to the Soffritto group.
For 6 weeks, volunteers received soffritto (100 g/day).
After the initial six-week phase, there was a two-week washout period, followed by a second six-week period in which participants were placed in the control group.
|
The intervention trial was a single-center, prospective, controlled, randomized two-arm longitudinal crossover trial lasting 16 weeks.
This duration encompassed a 2-week run-in period, a 6-week intervention period (either in the soffito or control group), a 2-week wash-out period, and another 6-week intervention period (soffritto or control group).
Other Names:
|
Experimental: Control group
After a two-week run-in phase, the participants (N=20) were randomly assigned to the control group.
For 6 weeks, the volunteers did not receive any product.
After the initial six-week run-in phase, there was a two-week washout period, followed by a second six-week period in which participants were switched to the Soffritto group (100g/day).
|
The intervention trial was a single-center, prospective, controlled, randomized two-arm longitudinal crossover trial lasting 16 weeks.
This duration encompassed a 2-week run-in period, a 6-week intervention period (either in the soffito or control group), a 2-week wash-out period, and another 6-week intervention period (soffritto or control group).
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes from baseline of platelet aggregation (induced by different agonists: arachidonic acid [1 mM], collagen [2 and 5 µM] and ADP [5 and 20 µM] at day 42
Time Frame: At days 0 and 42
|
By the light transmission technique LTA.
For all agonist results were expressed as the percentage of variation respect to the baseline value (100%).
|
At days 0 and 42
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes from baseline of glucose levels at day 42
Time Frame: At days 0 and 42
|
Using routine commercially available assays
|
At days 0 and 42
|
Changes from baseline of standard serum lipid profile (total cholesterol, high density lipoprotein-cholesterol, low density lipoprotein-cholesterol and triacylglycerols expressed as mg/dL) at day 42
Time Frame: At days 0 and 42
|
Routine commercially available assays were used for triglycerides, total cholesterol and high density lipoprotein cholesterol.
Low density lipoprotein cholesterol was calculated using the Friedewald equation
|
At days 0 and 42
|
Changes from baseline of vascular endothelial function (RHI, lnRHI, FRHI and AI@75) at day 42
Time Frame: At days 0 and 42
|
Digital plethysmography using the EndoPAT2000-device.
Endothelial function was given as the reactive hyperaemia index (RHI) and the arterial stiffness as the augmentation index (AI) and AI standardized to a pulse of 75/min (AI@75).
The natural logarithmically transformed RHI (lnRHI) values was also calculated.
The Framingham RHI (FRHI) was calculated as the natural log-transformation of the RHI
|
At days 0 and 42
|
Changes from baseline of hemogram profile at day 42
Time Frame: At days 0 and 42
|
Digital plethysmography using the EndoPAT2000-device
|
At days 0 and 42
|
Changes from baseline of hemodynamic profile at day 42
Time Frame: At days 0 and 42
|
Blood pressure monitor (Sphygmomanometer)
|
At days 0 and 42
|
Changes from baseline of hepatic enzymes (ALT, AST and GGT) at day 42
Time Frame: At days 0 and 42
|
Using routine commercially available assays
|
At days 0 and 42
|
Changes from baseline of renal markers (creatinine, urea and uric acid) at day 42
Time Frame: At days 0 and 42
|
Using routine commercially available assays
|
At days 0 and 42
|
Changes from baseline of BMI at day 42
Time Frame: At days 0 and 42
|
Dividing the body weight in kilograms by the square of height in meters (kg/m2)
|
At days 0 and 42
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ICCC-10 FRITOCARD
- CEN-20101016 (Other Grant/Funding Number: CDTI-Spanish Ministry of Competitivity and Economy (MINECO))
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Dietary Exposure
-
Loughborough UniversityKyowa Hakko Bio Co., Ltd.CompletedDietary ExposureUnited Kingdom
-
Oregon Health and Science UniversityCompleted
-
Société des Produits Nestlé (SPN)CompletedDietary ExposureUnited Kingdom
-
University of North Carolina, Chapel HillThe Bloomberg Family Foundation, Inc.CompletedDietary ExposureUnited States
-
Universitas Katolik Widya Mandala SurabayaCompletedDietary ExposureIndonesia
-
Société des Produits Nestlé (SPN)Recruiting
-
Washington University School of MedicineMichigan State University; Project Peanut Butter, Ghana; College of Health Sciences...Completed
-
International Agency for Research on CancerFederico II University; Imperial College London; Fondazione IRCCS Istituto Nazionale... and other collaboratorsCompleted
-
Martin-Luther-Universität Halle-WittenbergNot yet recruitingSafety Issues | Dietary Exposure
-
Northumbria UniversityCompletedMetabolic Disturbance | Dietary ExposureUnited Kingdom